Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Mereo BioPharma (MREO) Invested Capital (2020 - 2025)

Mereo BioPharma (MREO) has disclosed Invested Capital for 6 consecutive years, with $46.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Invested Capital rose 164.24% to $46.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $46.6 million, a 164.24% increase, with the full-year FY2024 number at $61.0 million, up 20.64% from a year prior.
  • Invested Capital was $46.6 million for Q3 2025 at Mereo BioPharma, down from $54.2 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $78.6 million in Q2 2024 to a low of -$72.5 million in Q3 2024.
  • A 5-year average of $41.6 million and a median of $50.5 million in 2023 define the central range for Invested Capital.
  • Peak YoY movement for Invested Capital: soared 167.6% in 2022, then crashed 232.59% in 2024.
  • Mereo BioPharma's Invested Capital stood at $19.4 million in 2021, then skyrocketed by 167.6% to $51.9 million in 2022, then dropped by 2.6% to $50.5 million in 2023, then grew by 20.64% to $61.0 million in 2024, then fell by 23.57% to $46.6 million in 2025.
  • Per Business Quant, the three most recent readings for MREO's Invested Capital are $46.6 million (Q3 2025), $54.2 million (Q2 2025), and $60.1 million (Q1 2025).